Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Kidney Cancer Clinical Trials

104 recruiting trials for Kidney Cancer. Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
104
Total Trials
104
Recruiting Now
4
Phase 3 Trials
10
Sponsors

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGNCT03702309

Liquid Biopsy Evaluation and Repository Development at Princess Margaret

The objective of this protocol is to develop an institution-wide liquid biopsy protocol that will establish a common process for collecting blood and corresponding archived tumor...

Sponsor: University Health Network, TorontoEnrolling: 25001 location
RECRUITINGNCT05539677

Biobank and Register of Patients With Agresive Tumors for Translational and Analytical Research

The investigators will collect biosamples of patient blood and tumour tissue for further immunological analysis of blood cell subpopulations, immunosupressive factors...

Sponsor: N.N. Petrov National Medical Research Center of OncologyEnrolling: 10001 location
RECRUITINGNCT06926374

Prospective Evaluation of Cornerstone Robotics Sentire Surgical System in Major Gastrointestinal and Urologic Surgery

Robotic assisted surgery has been performed for more than two decades with good success and safety profile. However, there was only one dominating robotic surgical system...

Sponsor: Chinese University of Hong KongEnrolling: 901 location
RECRUITINGNCT06138067

Patient Navigation Program to Improve Clinical Trial Enrollment in Cancer Patients

The goal of this clinical trial is to test the utility of patient navigation by comparing high intensity patient navigation to low intensity navigation approaches to improving...

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsEnrolling: 902 locations
RECRUITINGPhase 1 / Phase 2NCT00722228

Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors

This study is based on the finding that tumor cells that are grown in the laboratory can be modified in such a way that, when injected to the patient, they will stimulate his/her...

Sponsor: Hadassah Medical OrganizationEnrolling: 501 location
RECRUITINGNCT06206707

FMT in Checkpoint Inhibitor-mediated Diarrhea and Colitis

The goal of this clinical trial is to determine the outcome of patients with immune checkpoint inhibitor-mediated diarrhea/colitis (IMC) treated with faecal microbiota...

Sponsor: University of AarhusEnrolling: 201 location
RECRUITINGNCT07124000

DESTINY-PANTUMOUR04

This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior...

Sponsor: AstraZenecaEnrolling: 10017 locations
RECRUITINGNCT05725421

Transplantation of Reconstructed Renal Allografts Following Ex-Vivo Partial Nephrectomy

This study is designed to investigate a novel approach to offer more ESRD participants the benefits associated with renal transplantation by increasing the supply of available...

Sponsor: Case Comprehensive Cancer CenterEnrolling: 51 location
RECRUITINGPhase 1NCT06010875

A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors

This is a single-center, double-arm, open-label study. this study plans to evaluate the safety and efficacy of CD70-targeting CAR-T cells in the treatment of CD70-positive...

Sponsor: Chongqing Precision Biotech Co., LtdEnrolling: 481 location
RECRUITINGPhase 3NCT04510597

Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in...

This phase III trial compares the effect of adding surgery to a standard of care immunotherapy-based drug combination versus a standard of care immunotherapy-based drug...

Sponsor: SWOG Cancer Research NetworkEnrolling: 36420 locations
RECRUITINGNCT01793168

Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

CoRDS, or the Coordination of Rare Diseases at Sanford, is based at Sanford Research in Sioux Falls, South Dakota. It provides researchers with a centralized, international...

Sponsor: Sanford HealthEnrolling: 200002 locations
RECRUITINGPhase 2NCT07072728

Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder

This study is assessing the efficacy and safety of NPX-5 in psilocybin-assisted psychotherapy for the treatment of adjustment disorder due to cancer diagnosis. Who is it for?...

Sponsor: Psyence Australia Pty LtdEnrolling: 873 locations
RECRUITINGPhase 2NCT06161532

Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High...

Background: Rare tumors of the genitourinary (GU) tract can appear in the kidney, bladder, ureters, and penis. Rare tumors are difficult to study because there are not enough...

Sponsor: National Cancer Institute (NCI)Enrolling: 601 location
RECRUITINGNCT02087852

Kidney Cancer DNA Registry

This registry will help us develop better methods of: * Preventing these cancers * Diagnosing these cancers * Treating these cancers

Sponsor: Memorial Sloan Kettering Cancer CenterEnrolling: 7507 locations
RECRUITINGPhase 2NCT07489534

Study of PD-1Ab21-BCMA CAR-T Therapy for Consolidation of Multiple Myelomawith Renal Dysfunction

The purpose of this study is to determine the efficacy and safety of targeted BCMA CART cells secreting PD1 and interleukin 21 fusion protein immunotherapy for first-line...

Sponsor: Daihong LiuEnrolling: 251 location
RECRUITINGPhase 1NCT05581004

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With...

This is a first-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of enzelkitug when administered as a single agent and in...

Sponsor: Genentech, Inc.Enrolling: 45020 locations
RECRUITINGPhase 2NCT07225114

Translation of Acoustic Angiography: Contrast Enhanced Super Resolution (CESR) Imaging

This is a 4-arm, single-center study involving 40 participants. Ten healthy volunteers will be enrolled for system imaging optimization, and thirty (30) patients with previously...

Sponsor: UNC Lineberger Comprehensive Cancer CenterEnrolling: 401 location
RECRUITINGNCT06907095

Cohort Evaluation of Body Fluids Early Detection of Cancer in High-risk Individuals

LEAH is a prospective, observational, single-centre, non-randomised, open-label study of people at increased risk of cancer or malignant disease. The main objective of LEAH is to...

Sponsor: Gustave Roussy, Cancer Campus, Grand ParisEnrolling: 59091 location
RECRUITINGPhase 2NCT05768464

Postoperative Adjuvant Therapy for Non-clear Renal Cell Carcinoma With High-risk Recurrence Factors

The goal of this prospective, multicenter, single-arm clinical study is to evaluate the efficacy and safety of toripalimab in combination with axitinib for postoperative adjuvant...

Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolEnrolling: 302 locations
RECRUITINGPhase 1NCT04473781

Interstitial Brachytherapy for the Treatment of Unresectable/Unablatable Kidney Cancer

This phase I/II trial investigates the side effects of interstitial brachytherapy and to see how well it works in limiting the growth of large kidney cancer masses in patients...

Sponsor: Jonsson Comprehensive Cancer CenterEnrolling: 171 location
RECRUITINGNCT06995664

Partial Volume High-Dose Irradiation in Renal Cell Carcinoma for Intra-TUmoural Control ALongside Current Management

Prospective, randomised, feasibility study of patients with localised or metastatic renal cell carcinoma (RCC) comparing standard palliative dose radiotherapy to a high-dose...

Sponsor: Royal Marsden NHS Foundation TrustEnrolling: 241 location
RECRUITINGPhase 2NCT07229040

A Double-blind Non Inferiority Clinical Trial to Compare the Nephroprotection of Cilastatn Versus Thiosulfate in...

To compare cilastatin vs thiosulfatein renal protection in patients undergoing debulking surgery with intraoperative hyperthermic intraperitoneal chemotherapy with cisplatin

Sponsor: Hospital General Universitario Gregorio MarañonEnrolling: 901 location
RECRUITINGNCT06424080

Oncological and Perioperative Outcomes of Laparoscopic Versus Robotic Partial Nephrectomy for Treatment of Renal Tumors.

partial nephrectomy offers lower renal function impairment and equivalent oncological survival outcomes compared with radical nephrectomy in those with T1 tumors. As urology has...

Sponsor: Menoufia UniversityEnrolling: 201 location
RECRUITINGNCT06899789

Long-term Follow-up of Checkpoint Inhibitors-induced Ileo-colitis

This is a multicentric, observational study, including all European centres willing to take part. The multicentre nature is necessary for enhancing the generalisability of our...

Sponsor: Fondazione IRCCS Policlinico San Matteo di PaviaEnrolling: 2501 location
RECRUITINGNCT07117227

Validation of RCC Predicting Model With Emulated-target Trial

This single-center study utilizes real-world data (2012-2024) from 4700 renal cell carcinoma (RCC) patients at Peking University Third Hospital to: (1) Develop and validate a...

Sponsor: Peking University Third HospitalEnrolling: 47001 location
RECRUITINGNCT04712305

Urine Omics Predicting IO Therapy Responses in mRCC Patients

The study aims to identify urinary metabolite and protein markers that can predict anti-tumor efficacy and adverse events in subjects receiving IO-based therapies for metastatic...

Sponsor: National Taiwan University HospitalEnrolling: 4001 location
RECRUITINGNCT07540260

CAIX PET/ CT Guided Radiation Therapy in CcRCC.

This is a prospective, single-arm study in adults with recurrent or metastatic clear cell renal cell carcinoma (ccRCC). Participants will receive standard systemic therapy...

Sponsor: Peking University First HospitalEnrolling: 701 location
RECRUITINGPhase 1 / Phase 2NCT04724018

Sacituzumab Govitecan Plus EV in Metastatic UC

Phase I of this research study will assess what doses of Sacituzumab Govitecan and Enfortumab Vedotin can be safely combined in the treatment of metastatic urothelial carcinoma...

Sponsor: Dana-Farber Cancer InstituteEnrolling: 1061 location
RECRUITINGPhase 2NCT06962787

A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer

This Phase II study is a clinical study to explore the efficacy and safety of BL-B01D1 in combination with tyrosine kinase inhibitor (TKI) with or without pembrolizumab...

Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.Enrolling: 2601 location
RECRUITINGPhase 2NCT06889649

SABR Combined with Axitinib and Toripalimab in Recurrent or Metastatic RCC

This is a prospective, single-center clinical trial designed to evaluate the safety and efficacy of combining stereotactic ablative body radiotherapy (SABR) with the targeted...

Sponsor: Peking University First HospitalEnrolling: 301 location
RECRUITINGNCT06357416

The Man Van Project

National Health Service (NHS) England has commissioned The Royal Marsden Hospital NHS Foundation Trust to run a novel mobile clinical outreach service called 'Man Van' with the...

Sponsor: Royal Marsden NHS Foundation TrustEnrolling: 40001 location
RECRUITINGNCT07190638

Comparison of Outcomes and Surgical Time Between Cortical and Medullary Suture vs. Medullary-Only Suture: Cortex...

Renal function preservation is a growing concern in the surgical management of kidney tumors, particularly with the rise in chronic kidney disease worldwide. Recent surgical...

Sponsor: Brazilian Institute of Robotic SurgeryEnrolling: 802 locations
RECRUITINGNCT06262516

Nephroureterectomy With and Without Lymph Node Dissection for Upper Tract Urothelial Cell Carcinoma

The goal of this study is to conduct the first randomized-controlled trial to determine the oncologic efficacy of lymph node dissection in participants with upper tract urothelial...

Sponsor: Case Comprehensive Cancer CenterEnrolling: 944 locations
RECRUITINGNCT07301827

Study on the Diagnostic Value of Novel PET Molecular Imaging for Renal Cell Carcinoma

This study is a diagnostic study. This project aims to explore the clinical application value of PET imaging technologies targeting PSMA, CAIX, and CD70 in renal cell carcinoma....

Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyEnrolling: 661 location
RECRUITINGPhase 2 / Phase 3NCT05770037

DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive...

This clinical trial is looking at a drug called alectinib. Alectinib is approved as standard of care treatment for adult patients with certain types of lung cancer. This means it...

Sponsor: Cancer Research UKEnrolling: 3020 locations
RECRUITINGPhase 1NCT06623630

Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti;...

Treatment for relapsed/refractory multiple myeloma continues to evolve with the approval of highly effective anti-BCMA CAR T therapies in recent years. However, despite the high...

Sponsor: Washington University School of MedicineEnrolling: 161 location
RECRUITINGNCT06720532

Kidney Function and Risk Factors in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Undergoing...

The goal of this observational study is to determine the impact of 177Lutetium-Prostate Specific Membrane Antigen (PSMA) Radioligand Therapy (177Lu-PSMA-RLT) on kidney function...

Sponsor: Hannah SchaeferEnrolling: 1001 location
RECRUITINGPhase 1 / Phase 2NCT07551349

Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell Carcinoma

Phase 1/2 study evaluates the safety, feasibility, and preliminary antitumor activity of allogeneic dual-target CD70/CAIX CAR-NK cells after fludarabine/cyclophosphamide...

Sponsor: Beijing BiotechEnrolling: 361 location
RECRUITINGPhase 1 / Phase 2NCT05765084

Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line...

In this multicenter phase I/II trial, the programmed death-ligand 1 (PD-L1) inhibitor atezolizumab and dendritic cells (DCs) loaded with the mesothelioma-associated tumor antigen...

Sponsor: University Hospital, AntwerpEnrolling: 153 locations
RECRUITINGNCT07299357

Prospective Observational Trial of Image-guided Ablative STereotactic bOdy Radiation Therapy for Primary kidNey Cancer:...

The study objective is to evaluate the use of Stereotactic Body Radiotherapy (high dose of radiation in a few fractions) to cure primary renal cancer in those patients that are...

Sponsor: Istituto Clinico HumanitasEnrolling: 532 locations
RECRUITINGPhase 4NCT06764095

Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and...

This phase IV trial tests the impact of standard of care enfortumab vedotin and pembrolizumab followed by removal of all or part of the bladder (cytoreductive cystectomy) and/or...

Sponsor: Mayo ClinicEnrolling: 751 location
RECRUITINGNCT06908902

Prospective Study on the Safety and Efficacy of Robot-Assisted Laparoscopic Partial Nephrectomy With Renal Artery...

Renal tumors are common urological cancers, with over 430,000 new cases and more than 170,000 deaths globally in 2020. In China, renal cancer ranks third among urological...

Sponsor: The First Affiliated Hospital with Nanjing Medical UniversityEnrolling: 601 location
RECRUITINGPhase 1NCT04715191

Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid...

Patients may be considered if the cancer has come back, has not gone away after standard treatment or the patient cannot receive standard treatment. This research study uses...

Sponsor: Baylor College of MedicineEnrolling: 241 location
RECRUITINGNCT06391099

Ketogenic Dietary Intervention to Improve Response to Immunotherapy in Patients With Metastatic Melanoma and Metastatic...

This phase I trial studies how well a ketogenic dietary intervention works to improve response to immunotherapy in patients with melanoma and kidney cancer that has spread from...

Sponsor: Ohio State University Comprehensive Cancer CenterEnrolling: 601 location
RECRUITINGNCT07037589

Women With isoLated acUte cyStitis and Macroscopic Hematuria. Is Further Investigation Needed?

This prospective multicenter observational study evaluates whether women ≥50 years with isolated acute hemorrhagic cystitis (AHC) and macroscopic hematuria require full malignancy...

Sponsor: Vastra Gotaland RegionEnrolling: 3001 location
RECRUITINGNCT04902846

Immune Checkpoint Inhibitors Nephrotoxicity

In recent years, immunotherapy has been postulated as one of the most effective strategy in the fight against cancer. The greatest success in this field has been achieved through...

Sponsor: R. Laura Vicente VicenteEnrolling: 2202 locations
RECRUITINGPhase 2NCT05969860

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer

This clinical trial studies the effect of cancer directed therapy given at-home versus in the clinic for patients with cancer that may have spread from where it first started to...

Sponsor: Mayo ClinicEnrolling: 2202 locations
RECRUITINGNCT06337942

Deceased Donor Bladder or Combined Kidney-bladder Transplantation: a Phase 0 First-in-human Study

The goal of this clinical trial is to demonstrate the feasibility of bladder transplantation in patients with terminal bladder diseases who would benefit from a new bladder or a...

Sponsor: University of California, Los AngelesEnrolling: 51 location
RECRUITINGPhase 1NCT07419841

A Phase 1 Study of the Safety and Tolerability of CTX-10726

This is a Phase 1, open-label, first-in-human study of CTX-10726 monotherapy in patients with metastatic or locally advanced malignancies. The study will be conducted in 2...

Sponsor: Compass TherapeuticsEnrolling: 704 locations
RECRUITINGPhase 1NCT07369505

Sapu003 in Advanced mTOR-sensitive Solid Tumors

This is a phase 1b, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics of Sapu003 in combination with Exemestane in in patients with advanced...

Sponsor: SAPU NANO (US) LLCEnrolling: 271 location

Showing 50 of 104 trials.Search all Kidney Cancer trials

Frequently Asked Questions

There are currently 104 clinical trials for Kidney Cancer, with 104 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Kidney Cancer, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 4 Phase 3 trials for Kidney Cancer, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.

this entity is one of the data points covered by this site’s U.S. clinical trials and research registries dataset. The detail above comes directly from the NIH ClinicalTrials.gov registry; the context that follows situates the headline numbers against the broader distribution across active and historical clinical trials.

Every number on this page links back to the NIH ClinicalTrials.gov registry; the methodology page describes the inputs, refresh cadence, and known limitations of the underlying data product.

Practical use of this page is in combination with the comparison and ranking pages elsewhere on the site, which surface the same data for this entity’s peers within active and historical clinical trials. A single-entity reading without peer context can be misleading when an entity is an outlier on one axis but typical on another.